Linked Data API

Show Search Form

Search Results

1521788
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, for what reason her Department included branded (a) generic and (b) biosimilar medicines that delivered savings to the NHS within the current voluntary scheme for branded medicines pricing and access scheme. more like this
tabling member constituency Harlow more like this
tabling member printed
Robert Halfon remove filter
uin 62792 more like this
answer
answer
is ministerial correction false more like this
date of answer remove maximum value filtermore like thismore than 2022-11-01
answer text <p>Medicines which are required to be prescribed by brand name, including some branded generics and biosimilars, are not interchangeable. Therefore, competitive forces will not act in the same way as for generic medicines and price regulation is justified. The inclusion of these medicines in the Voluntary Scheme for Branded Medicines Pricing and Access was agreed with industry in 2019.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2022-11-01T12:23:25.943Zmore like thismore than 2022-11-01T12:23:25.943Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
3985
label Biography information for Robert Halfon more like this